The HIV type 1 protease L10I minor mutation decreases replication capacity and confers resistance to protease inhibitors

AIDS Research and Human Retroviruses

Volumn 27, Issue 1, 2011, Pages 65-70

  Flor Parra, Fernando ^a   Pérez Pulido, Antonio J ^b   Pachón, Jerónimo ^a   Pérez Romero, Pilar ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; SAQUINAVIR;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG BINDING SITE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; TETRAZOLIUM SALTS; THIAZOLES; VIRUS REPLICATION;

EID: 78651422157     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0072     Document Type: Article

References (39)

1. Barbour JD, Wrin T, Grant RM, et al.: Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 2002;76(21):11104-11112.
2. Colonno R, Rose R, McLaren C, Thiry A, Parkin N, and Friborg J: Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1- infected patients receiving ATV-containing regimens. J Infect Dis 2004;189(10):1802-1810.
3. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, and Lamarre D: Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997;71(2):1089-1096.
4. Nijhuis M, Deeks S, and Boucher C: Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 2001;14(1):23-28.
5. Quinones-Mateu ME and Arts EJ: HIV-1 fitness: Implicationsfor drug resistance, disease progression, and global epidemic evolution. In: HIV Sequence Compendium (Korber B, Ed.). Theoretical Biology and Biophysics Group, Los Alamos, NM, 2001, pp. 134-170.
6. Shafer RW and Schapiro JM: HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev 2008;10(2):67-84.
7. Martinez-Picado J, Savara AV, Sutton L, and D'Aquila RT: Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999;73(5): 3744-3752.
8. Prado JG, Wrin T, Beauchaine J, et al.: Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002;16(7):1009-1017.
9. Zennou V, Mammano F, Paulous S, Mathez D, and Clavel F: Loss of viral fitness associated with multiple Gag and Gag- Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998;72(4):3300-3306.
10. De Luca A, Weidler J, Di Giambenedetto S, et al.: Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure. J Acquir Immune Defic Syndr 2007;45(4):411-417.
11. Daar ES, Kesler KL, Wrin T, et al.: HIV-1 pol replication capacity predicts disease progression. AIDS 2005;19(9):871-877.
12. Clemente JC, Hemrajani R, Blum LE, Goodenow MM, and Dunn BM: Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N. Biochemistry 2003;42(51):15029-15035.
13. Mammano F, Trouplin V, Zennou V, and Clavel F: Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug. J Virol 2000;74(18): 8524-8531.
14. Margerison ES, Maguire M, Pillay D, Cane P, and Elston RC: The HIV-1 protease substitution K55R: A protease-inhibitorassociated substitution involved in restoring viral replication. J Antimicrob Chemother 2008;61(4):786-791.
15. Nijhuis M, Schuurman R, de Jong D, et al.: Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999;13(17):2349-2359.
16. Martinez-Picado J, Savara AV, Shi L, Sutton L, and D'Aquila RT: Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 2000;275(2): 318-322.
17. Kantor R, Katzenstein DA, Efron B, et al.: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med 2005;2(4):e112.
18. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, and Shafer RW: Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003;31(1):298-303.
19. Sukasem C, Churdboonchart V, Chasombat S, et al.: Prevalence of antiretroviral drug resistance in treated HIV-1 infected patients: Under the initiative of access to the NNRTI-based regimen in Thailand. J Chemother 2007;19(5): 528-535.
20. Han X, Zhang M, Dai D, et al.: Genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV/AIDS patients living in Liaoning Province, China: Baseline prevalence and subtype-specific difference. AIDS Res Hum Retroviruses 2007;23(3):357-364.
21. McConnell MJ, Docobo-Perez F, Mata RC, et al.: Molecular epidemiology of HIV type 1 in newly diagnosed patients in southern Spain. AIDS Res Hum Retroviruses 2008;24(6):881-887.
22. Rodrigues R, Scherer LC, Oliveira CM, et al.: Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus Res 2006;116 (1-2):201-207.
23. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, and Perrin L: Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999;354(9180):729-733.
24. Maeda Y, Venzon DJ, and Mitsuya H: Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis 1998;177(5):1207- 1213.
25. Perno CF, Cozzi-Lepri A, Balotta C, et al.: Impact of mutations conferring reduced susceptibility to lamivudine on the response to antiretroviral therapy. Antivir Ther 2001; 6(3):195-198.
26. Perno CF, Cozzi-Lepri A, Balotta C, et al.: Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis 2001; 184(8):983-991.
27. Zolopa AR, Shafer RW, Warford A, et al.: HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 1999;131(11):813-821.
28. Pear WS, Nolan GP, Scott ML, and Baltimore D: Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993;90(18):8392-8396.
29. Harada S, Koyanagi Y, and Yamamoto N: Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 1985;229(4713): 563-566.
30. Garcia-Perez J, Perez-Olmeda M, Sanchez-Palomino S, Perez- Romero P, and Alcami J: A new strategy based on recombinant viruses for assessing the replication capacity of HIV-1. HIV Med 2008;9(3):160-171.
31. Garcia-Perez J, Sanchez-Palomino S, Perez-Olmeda M, Fernandez B, and Alcami J: A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1. J Med Virol 2007;79(2):127-137.
32. Wang J and Wilkinson MF: Site-directed mutagenesis of large (13-kb) plasmids in a single-PCR procedure. Biotechniques 2000;29(5):976-978.
33. Mata RC, Flor-Parra F, Viciana P, Lopez-Cortes LF, and Perez-Romero P: Virological and immunological stability in HIV infected patients undergoing partial-treatment interruption. J Clin Virol 2009;45(4):362-366.
34. Pauwels R, Balzarini J, Baba M, et al.: Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20(4):309-321.
35. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009;17(5):138-145.
36. Sukasem C, Churdboonchart V, Sukeepaisarncharoen W, et al.: Genotypic resistance profiles in antiretroviral-na've HIV-1 infections before and after initiation of first-line HAART: Impact of polymorphism on resistance to therapy.Int J Antimicrob Agents 2008;31(3):277-281.
37. Kempf DJ, Isaacson JD, King MS, et al.: Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001;75(16):7462-7469.
38. Kim R and Baxter JD: Protease inhibitor resistance update: Where are we now? AIDS Patient Care STDS 2008;22(4):267-277.
39. Wang W and Kollman PA: Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance. Proc Natl Acad Sci USA 2001;98(26):14937-14942.